BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 1 Baseline characteristics of hepatocellular carcinoma patients treated with second-line regorafenib combination with programmed cell death-1 inhibitor or monotherapy, n (%)
Characteristics
Overall (n = 140)
R group (n = 39)
RP group (n = 101)
P value
Age0.811
    < 6599 (70.7)27 (69.2)72 (71.3)
    ≥ 6541 (29.3)12 (30.8)29 (28.7)
Gender0.652
    Female22 (15.7)7 (17.9)15 (14.9)
    Male118 (84.3)32 (82.1)86 (85.1)
Smoking0.839
    No95 (67.9)28 (71.8)67 (66.3)
    Yes39 (27.9)10 (25.6)29 (28.7)
    Unknown6 (4.3)1 (2.6)5 (5.0)
Drinking0.203
    No103 (73.6)26 (66.7)77 (76.2)
    Yes30 (21.4)12 (30.8)18 (17.8)
    Unknown7 (5.0)1 (2.6)6 (5.9)
Hepatitis B infection0.908
    No31 (22.1)8 (20.5)23 (22.8)
    Yes107 (76.4)31 (79.5)76 (75.2)
    Unknown2 (1.4)0 (0.0)2 (2.0)
Hepatitis C infection0.106
    No134 (95.7)38 (97.4)96 (95.0)
    Yes1 (0.7)1 (2.6)0 (0.0)
    Unknown5 (3.6)0 (0.0)5 (5.0)
Diabetes1.000
    No126 (90.0)36 (92.3)90 (89.1)
    Yes13 (9.3)3 (7.7)10 (9.9)
    Unknown1 (0.7)0 (0.0)1 (1.0)
Hypertension0.285
    No99 (70.7)25 (64.1)74 (73.3)
    Yes41 (29.3)14 (35.9)27 (26.7)
First-line ICI therapy0.224
    No53 (37.9)14 (35.9)39 (38.6)
    Yes72 (51.4)18 (46.2)54 (53.5)
    Unknown15 (10.7)7 (17.9)8 (7.9)
Tumor size0.323
    ≤ 5 cm46 (32.9)12 (30.8)34 (33.7)
    > 5 cm25 (17.9)10 (25.6)15 (14.9)
    Unknown69 (49.3)17 (43.6)52 (51.5)
CNLC0.715
    IIa + IIb50 (35.7)13 (33.3)37 (36.6)
    IIIa + IIIb90 (64.3)26 (66.7)64 (63.4)
Child-Pugh class0.714
    A74 (52.9)22 (56.4)52 (51.5)
    B21 (15.0)5 (12.8)16 (15.8)
    C2 (1.4)0 (0.0)2 (2.0)
    Unknown43 (30.7)12 (30.8)31 (30.7)
ECOG PS
    022 (15.7)5 (12.8)17 (16.8)0.908
    126 (18.6)9 (23.1)17 (16.8)
    29 (6.4)2 (5.1)7 (6.9)
    31 (0.7)0 (0.0)1 (1.0)
    Unknown82 (58.6)23 (59.0)59 (58.4)
Portal vein invasion tumor
    No66 (47.1)19 (48.7)47 (46.5)0.702
    Yes30 (21.4)9 (23.1)21 (20.8)
    Unknown44 (31.4)11 (28.2)33 (32.7)
Sites of metastasis
    Lung28 (45.2)9 (40.9)19 (47.5)
    Bone8 (12.9)3 (13.6)5 (12.5)
    Lymph node16 (25.8)6 (27.3)10 (25.0)
    Others10 (16.1)4 (18.2)6 (15.0)
Laboratory indicators, median [IQR]
    Platelet (× 109/L)151.00 [111.00, 217.25]152.00 [110.50, 178.00]151.00 [111.00, 222.00]0.577
    Hemoglobin (g/L)132.00 [107.00, 144.25]127.00 [114.50, 145.50]134.00 [107.00, 143.00]0.961
    ALT (IU/L)35.00 [23.00, 65.00]37.00 [23.00, 54.00]34.00 [23.00, 73.00]0.705
    AST (IU/L)41.50 [29.00, 82.75]46.00 [31.00, 104.00]41.00 [27.00, 74.00]0.265
    ALB (g/L)39.70 [36.12, 43.90]39.70 [36.45, 43.90]39.70 [36.20, 43.90]0.917
    TBIL (μmol/L)17.20 [11.15, 23.30]16.30 [13.20, 26.30]17.30 [10.65, 21.90]0.430
    DBIL (μmol/L)7.95 [5.18, 11.73]7.70 [5.00, 12.00]8.00 [5.20, 11.35]0.631
    PT (s)12.55 [11.80, 13.55]12.70 [11.90, 13.85]12.50 [11.70, 13.30]0.503
    INR1.03 [0.98, 1.11]1.04 [0.90, 1.10]1.02 [0.99, 1.13]0.465
    AFP (ng/mL)124.20 [7.60, 2000.00]101.10 [7.85, 1978.90]124.20 [7.20, 2403.61]0.970
Initial daily dose of regorafenib
    40 mg6 (4.3)1 (2.6)5 (5.0)0.057
    80 mg65 (46.4)13 (33.3)52 (51.5)
    120 mg12 (8.6)6 (15.4)6 (5.9)
    160 mg18 (12.9)5 (12.8)13 (12.9)
    Unknown39 (27.9)14 (35.9)25 (24.8)


Write to the Help Desk